Latanoprost Noridem

Latanoprost, the active ingredient in Latanoprost Noridem, is a prostaglandin F2α analog presented as an ophthalmic solution for ocular use. It enhances uveoscleral outflow of aqueous humor, thereby reducing intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension.

GNH USA supplies Latanoprost Noridem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing EU‑sourced quality for eye‑care professionals. All batches meet European Pharmacopoeia standards and are shipped under controlled conditions to preserve sterility, through validated logistics networks.

Latanoprost is a prostaglandin analog used to lower intra‑ocular pressure in glaucoma‑related conditions.

- Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. - Ocular hypertension: lowers pressure to prevent conversion to glaucoma. - Secondary open‑angle glaucoma: helps control pressure when other causes are present.

Latanoprost may cause ocular and systemic reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Eyelash changes: increased length, thickness, or darkness. - Iris pigmentation: gradual darkening of the iris. - Eye irritation: foreign‑body sensation or mild discomfort. - Blurred vision: transient visual disturbance after instillation. - Periorbital skin darkening: mild hyperpigmentation around the eye.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, itching, or rash requiring medical attention. - Paradoxical IOP increase: unexpected rise in intra‑ocular pressure. - Corneal edema: swelling of the cornea that can affect vision. - Uveitis: inflammation of the uveal tract. - Macular edema: fluid accumulation in the central retina, potentially impairing central vision.

Before using Latanoprost, consider the following safety measures.

- Monitor IOP: measure intra‑ocular pressure before and after therapy initiation. - Avoid contact lens use: discontinue lenses for at least six weeks after starting treatment. - Assess for ocular infections: do not use if an active eye infection is present. - Pregnancy and lactation: safety not established; use only if benefit outweighs potential risk. - Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concurrent prostaglandin analog eye drops: may increase risk of ocular side effects. - Systemic carbonic anhydrase inhibitors: additive IOP‑lowering effect may cause hypotony.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: may reduce latanoprost efficacy. - Non‑steroidal anti‑inflammatory eye drops: may increase ocular irritation. - Beta‑blocker eye drops: additive IOP reduction; monitor pressure closely.